David Cory, Eiger BioPharmaceuticals CEO (Eiger via MultiVu)
March 17, 2022 10:12 AM EDTUpdated 01:05 PM
R&D
Coronavirus

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

John Carroll

Editor & Founder

The big hey­day of mar­ket delir­i­um re­lat­ed to any­thing pos­i­tive in new Covid-re­lat­ed da­ta has pe­tered out as Omi­cron pass­es over, but lit­tle Eiger Bio­Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times